New breast cancer Drug's absorption tested in healthy volunteers

NCT ID NCT06619873

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested the drug HRS-8080 in 24 healthy adults to see how well it is absorbed and whether food changes its levels in the body. Participants took single doses under different conditions, including fasting and with low- or high-fat meals. The results will help design future trials for breast cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HRS-8080

What this could lead to

If successful, this study could help determine the best way to take HRS-8080 in future trials for breast cancer.

What could go wrong

This is a very early, small study in healthy people, not patients. It only measures how the drug moves through the body, not whether it works against cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Frist Affiliated Hospital of USTC (Anhui Provincial Hospital)

    Hefei, Anhui, 230001, China